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Abstract
Innate lymphoid cells (ILCs) are a heterogeneous family of immune
cells that play a critical role in a variety of immune processes
including host defence against infection, wound healing and tissue
repair. Whether these cells are involved in lipid-dependent immu-
nity remains unexplored. Here we show that murine ILCs from a
variety of tissues express the lipid-presenting molecule CD1d,
with group 3 ILCs (ILC3s) showing the highest level of expression.
Within the ILC3 family, natural cytotoxicity triggering receptor
(NCR)CCR6+ cells displayed the highest levels of CD1d. Expression
of CD1d on ILCs is functionally relevant as ILC3s can acquire lipids
in vitro and in vivo and load lipids on CD1d to mediate presenta-
tion to the T-cell receptor of invariant natural killer T (iNKT) cells.
Conversely, engagement of CD1d in vitro and administration of
lipid antigen in vivo induce ILC3 activation and production of IL-22.
Taken together, our data expose a previously unappreciated role
for ILCs in CD1d-mediated immunity, which can modulate tissue
homeostasis and inflammatory responses.
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Introduction
Innate lymphoid cells (ILCs) are a family of immune cells that play
a central role in a variety of physiological processes including
immune regulation, modulation of interactions with the microbiota,
tissue repair and lymphoid tissue development [1]. ILCs can be clas-
sified in three families based on their cytokine secretion and the
transcription factors required for their development: ILC1s (T-bet+)
produce IFN-c; ILC2s (GATA-3+) secrete IL-5 and IL-13; and ILC3s
(RORct+) produce IL-17 and IL-22 [2]. Accordingly, ILCs can modu-
late immune cell function through cytokine secretion but also
through direct cell–cell interactions. Recent studies have identified
an unexpected function for ILCs as antigen presenting cells (APCs)
in the regulation of CD4+ T-cell immunity. As such, both ILC2s and
ILC3s can internalize and present antigens on MHC-II to control
cognate T-cell activation [3–7], T helper 17 cell differentiation [8]
and the intestinal selection of commensal bacteria-specific CD4+
T cells [9]. Concurrently, ILC–T-cell crosstalk promotes ILC
activation and cytokine production [4,5], evidencing a bidirectional
dialogue between the innate and adaptive immune systems.
Similar to the MHC-dependent recognition of protein antigens by
conventional T cells, a broad range of lipids associated with CD1d
molecules specifically activate a population of unconventional T
cells called invariant natural killer T (iNKT) cells [10,11]. Conse-
quently, iNKT cells recognize through their T-cell receptors (TCR)
CD1d-restricted self-lipids as well as lipids from pathogenic bacteria,
commensals or fungi, contributing to the establishment of immune
homeostasis and to anti-microbial, anti-tumour and autoimmune
responses [10,11]. Evidence suggests that the context of lipid
presentation provided by diverse CD1d+ APCs can shape the
outcome of immune responses, by tuning the extent of iNKT cell
activation, their proliferation and their pattern of cytokine secretion
[12–14]. Conversely, iNKT cell–APC interactions can modulate APC
activation and function [14–20]. For instance, iNKT cell activation
in response to glycolipid recognition results in CD40 ligand-dependent
maturation of dendritic cells (DC), favouring cross-presentation
and enhancing CD4, CD8 and B-cell responses [18–20]. Remarkably,
engagement of CD1d is sufficient to induce activation and secretion
of cytokines by both professional (DCs, monocytes) and unconven-
tional (intestinal epithelial cells; IECs) APCs resulting in modulation
of immunity in homeostasis and inflammation [14,21–23]. For
example, ligation of CD1d in IEC leads to secretion of IL-10 render-
ing protective effects in murine models of inflammatory bowel
disease (IBD) [14,21].
ILCs are emerging as central regulators of immunity, yet their
possible contribution to lipid-dependent immune responses has
never been explored. Here we show that ILCs from murine tissues
express the lipid-presenting molecule CD1d with the highest levels
of expression corresponding to ILC3s. Using fluorescent lipids and
presentation assays, we demonstrate that primary ILC3s are able to
internalize and load lipids on CD1d for recognition by the TCR of
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iNKT cells. Conversely, engagement of CD1d on ILC3s in vitro and
administration of antigenic lipids in vivo induce ILC3 activation and
secretion of IL-22. Thus, our data reveal a previously unknown
function for ILC3s on CD1d-dependent immunity.
Results and Discussion
ILCs express CD1d
To investigate the expression of the lipid-presenting molecule
CD1d by ILCs, we first identified them as lineage
(Lin)CD45+CD127+ cells and then used the expression of T-bet,
GATA-3 and RORct to discriminate the ILC1, ILC2 and ILC3 popu-
lations, respectively (Figs 1 and EV1). We detected CD1d expres-
sion in the putative ILC population (LinCD45+CD127+) within
the mesenteric lymph nodes (mLN), spleen, Peyer’s patches (PP),
small intestinal lamina propria (SI-LP), colonic LP and lung from
WT mice in comparison with ILCs from CD1d-deficient mice
(Fig EV1A). The level of CD1d expression in ILCs was generally
comparable to DCs and at least 10 times higher than CD45 cells
(Fig 1A). In all analysed tissues, RORct+ ILCs exhibited the high-
est levels of CD1d amongst the ILC populations, while T-bet+ ILCs
showed the lowest levels (Fig 1B). Previous studies have shown
that intestinal RORct+ ILCs display a gradient of T-bet that
controls their fate and function and ILC3s can up-regulate T-bet
and down-regulate RORct acquiring functional and phenotypical
features of ILC1s [24,25]. Accordingly, we detected that intestinal
RORct+ ILCs show variable expression of T-bet, which correlated
inversely with the levels of CD1d (Figs 1B and EV1B and C).
Finally, analysis of gene expression by quantitative PCR showed
CD1d mRNA expression on ILC3s sorted from the tissues of WT
mice in comparison with ILC3s isolated from CD1d-deficient mice
(Fig 1C). Thus, ILCs express CD1d with the higher levels of
expression corresponding to RORct+ ILC3s.
The ILC3 population is heterogeneous and comprises several
subfamilies with distinctive phenotypic and functional characteris-
tics including: (i) lymphoid tissue inducer (LTi) cells
(CCR6+NKp46) which are crucial for the formation of secondary
lymphoid organs and produce lymphotoxin, IL-17A and IL-22. LTi
cells include CD4 and CD4+ cells; (ii) natural cytotoxicity trigger-
ing receptor (NCR) ILC3s (NKp46) secrete IL-17A and/or IL-22
and have been associated with inflammatory conditions. NCR
ILC3s can give rise to NCR+ ILC3s in a process dependent on T-bet;
and (iii) NCR+ ILC3s (NKp46+) that secrete IL-22 but not IL-17A
and participate in the regulation of intestinal homeostasis [2,26]. To
interrogate the levels of CD1d expression in the different ILC3
subpopulations, we performed additional phenotypical analyses of
ILC3s from different tissues (Figs 1D and E, and EV1–EV3). As
previously described, we found that the majority of RORct+ ILC3s
in the mLN were NCRCCR6+ cells [7] which expressed high levels
of CD1d (Fig 1D and E) and lymphotoxin-alpha (LTA) mRNA but
lacked T-bet (Fig EV1C and D). Within the SI-LP, we found low
CD1d expression in NCR+ and NCRCCR6 ILC3s in comparison
with NCRCCR6+ cells (Fig 1D and E). Finally, CD1dhi ILC3 showed
high expression of CD117 (c-kit), lacked PLZF, and showed hetero-
geneous expression of MHC-II, CD4, and CD90, which were also
differentially expressed on RORct+ ILCs from various tissues
(Figs EV2 and EV3). Thus, ILCs express CD1d with the higher levels
of expression corresponding to NCRCCR6+ ILC3s.
RORct+CCR6+ ILC3s are a developmentally independent subset
originally described to promote lymphoid organogenesis and which
are major producers of IL-22 in homeostatic conditions and during
infection [24,27]. In the intestine, RORct+CCR6+ ILC3s expressing
MHC-II control intestinal homeostasis through cognate interactions
with CD4+ T cells [3,8,9]. In the adult spleen, RORct+CCR6+ ILC3s
promote CD4+ T-cell responses and enhance antibody production
by marginal zone B cells [4,28]. The fact that CD1d expression is
particularly high in RORct+CCR6+ ILC3s points towards a possible
contribution of ILC3s to CD1d-mediated immunity either in the
establishment of mucosal homeostasis or during inflammatory or
infectious immune responses.
ILC3s internalize lipids and mediate CD1d-dependent
lipid presentation
Next, we investigated the capacity of ILCs to internalize and load
lipids on CD1d for presentation to the TCR of iNKT cells (Fig 2).
Because ILC3s express the highest levels of surface CD1d (Fig 1),
we focussed on this population for our functional assays.
First, we tested the ability of ILC3s to acquire lipids by incubat-
ing sort-purified ILC3s with a fluorescent synthetic form of the
CD1d-binding iNKT cell-activating model lipid aGalCer (BODIPY-
aGalCer; Fig 2A). After incubation with fluorescent lipids in vitro,
ILC3s exhibited an increase in fluorescence intensity (comparable to
control DCs) indicative of an ability to acquire lipid antigens, while
lipid uptake was severely impaired when incubation was performed
at 4°C (Fig 2A). Since ILC3s are located in the marginal zone of the
spleen [28] where lipids can be efficiently retained when arriving in
the circulation [29], we tested whether splenic ILC3s have the
capacity to acquire lipid antigens in vivo (Fig 2B). To investigate
this, we injected fluorescent lipids intravenously in WT mice and
analysed lipid acquisition by ILC3s and DCs by flow cytometry. We
observed that 16 h after lipid injection, a proportion of splenic ILC3s
and DCs showed an increase in fluorescence intensity revealing
their ability to acquire lipids in vivo (Fig 2B). Multiple mechanisms
may collaborate to mediate lipid internalization by ILC3s and such
processes often are determined by the nature of the antigen (i.e.
lipoproteins, particulate material, pathogens). A variety of receptors
expressed by many cell types (such as low-density lipoprotein recep-
tor (LDL-R) or scavenger receptors) have been proposed to mediate
lipid antigen uptake and direct such lipids towards the CD1d presen-
tation pathway [30–32]. For instance, exogenous lipids can be incor-
porated into VLDL particles, which can then be internalized through
LDL receptor-mediated uptake [31,32]. Moreover, the uptake of
pathogens or particulate material by phagocytosis delivers exoge-
nous lipid antigens into the endocytic system, where CD1d mole-
cules can bind them [30]. Importantly ILC3s can internalize proteins
and latex beads [3,4] as well as lipids, which suggests that they may
be able to use a variety of mechanisms to sample their environ-
ment.
Next, we examined the capacity of ILC3s to load lipids on CD1d
and to present them to iNKT cells (Fig 2C–F). Sort-purified ILC3s
(from mLN or spleen) were pre-incubated with lipids for 2 h and
co-cultured with iNKT hybridoma cells (DN32.D3). As shown in
Fig 2C, aGalCer was efficiently presented by ILC3s as defined by
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Figure 1. CD1d expression on ILCs.
A Flow cytometry for CD1d expression (top) and CD1d mean fluorescence intensity (MFI; bottom) on CD45 cells, ILCs (LinCD45+CD127+), DCs (CD11c+) and B cells
(B220+) of the depicted tissues from WT mice (n = 4).
B Flow cytometry profiles showing gating strategy (dot plots), CD1d expression (histograms) and CD1d MFI (bars) in T-bet+ (empty profile), GATA-3+ (dark grey), RORct+
(light grey) and T-bet+RORct+ (dotted line) ILCs in mLN, spleen, PP and SI-LP (n = 5). Numbers indicate percentage of cells in the depicted gates.
C Quantitative RT–PCR analysis of mRNA encoding CD1d in freshly isolated ILC3s (from mLN of CD1d-deficient mice and mLN and spleen of WT mice), B cells and DCs
(n = 3). Results are normalized to those of GAPDH; RE, relative expression. **P < 0.01 (two-tailed unpaired t-test).
D Flow cytometry profiles showing NKp46 and RORct expression in LinCD45+ cells; CD1d and CCR6 expression in NCR ILC3s; and CD1d and CD4 expression in
NCRCCR6+ ILC3s from mLN and SI-LP (n = 4). Numbers indicate percentage of cells in the depicted gates.
E CD1d expression (histograms) and CD1d MFI in NCR+ (empty profile), NCRCCR6 (dark grey) and NCRCCR6+ (light grey) ILC3s from mLN and SI-LP (n = 4).
Data information: Graphs represent mean  SEM. Data are from three (A, C–E) or five (B) independent experiments.
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IL-2 production by iNKT cells. Importantly, lipid presentation was
dependent on CD1d as IL-2 secretion was strongly reduced in the
presence of a CD1d-blocking antibody (Fig 2C). To further test
whether ILC3s could mediate CD1d-dependent lipid presentation
A
C
D
E
F
B
Figure 2.
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in vivo, we loaded sort-purified ILC3s with lipids (or PBS as
control), transferred them into WT recipients and measured activa-
tion of iNKT cells sort-purified from spleen, mLN and SI-LP of the
recipient mice (Fig 2D–F). Lipid-loaded ILC3s induced activation of
iNKT cells as evidenced by an increase in the expression of
cytokines detected by qPCR (Fig 2E). Consistent with these data,
intracellular stainings showed increased IFN-c and IL-4 production
by splenic iNKT cells from mice receiving lipid-loaded ILC3s
(Fig 2F).
Altogether our data demonstrate that ILC3s can internalize lipids,
load them on CD1d and present them to iNKT cells both in vitro and
in vivo. The capacity of ILC3s to mediate CD1d-dependent lipid
presentation points towards an ILC3-iNKT cell dialogue that could
modulate the initiation and/or progression of the immune response.
It is worth noting that in the adult spleen, both ILC3 and iNKT cells
are located in the splenic marginal zone [28,29], which may favour
their crosstalk and the early initiation of immune responses. Within
the intestine, iNKT cells function and features are modulated by
CD1d-dependent recognition of commensal-derived lipids [33–35].
Since ILC3s modulate CD4+ T-cell responses to commensal bacteria
[3,8,9], it is conceivable that they could internalize and present
commensal-derived lipids to iNKT cells consequently regulating
intestinal iNKT cell immunity. Further studies will allow defining
the functional consequences of ILC3-mediated lipid presentation
in vivo both in homeostasis and during inflammatory and infectious
responses.
Engagement of CD1d on ILC3s drives IL-22 secretion
Next, we investigated the consequences of CD1d expression for
ILCs’ homeostasis and function. First, we tested whether CD1d
expression and/or NKT cells could influence the ILC populations in
steady state. T cells are known to regulate ILC numbers and func-
tion [7,36] and ILC populations are altered in RAG/, TCRa/ and
ZAP70/ mice that show a marked increase in the percentage of
ILC2s in their mLN at the expense of ILC3s [7]. Likewise, NKT cells
regulate immune cells in steady state including memory CD8+ T
cells and IgE production by B cells [37]. To determine whether NKT
cells/CD1d regulate ILC development, we examined ILCs in CD1d-
deficient mice (which also lack NKT cells; Figs 3A and B, and EV4).
We found that ILC populations were comparable in CD1d/ mice
and WT littermates, suggesting that neither CD1d nor NKT cells play
a major role in the regulation of ILC development and/or homeo-
stasis (Figs 3A and B, and EV4).
We then explored whether CD1d expression can shape the func-
tion of ILC3s. Previous studies have shown that engagement of
CD1d results in secretion of cytokines by both professional and
unconventional APCs including IL-10 secreted by IEC and IL-12 by
DCs and monocytes [21,22]. Consequently, engagement of epithelial
CD1d renders protective effects in mouse models of IBD, while
CD1d-mediated production of IL-12 by APCs leads to protection
against viral infection [14,23]. To study whether CD1d could regu-
late ILC3 function, we performed antibody-mediated cross-linking of
CD1d on ILC3s and measured changes in the expression of IL22,
IL17A, LTA and LTB (cytokines typically produced by ILC3s) as well
as TNFSF13B (BAFF), TNFSF13 (APRIL) and CD40LG (CD40L;
factors by which ILC3s modulate B-cell function [28]; Figs 3C and
EV5). Strikingly, CD1d ligation on ILC3s resulted in a prominent
increase in the expression of IL22 mRNA (Fig 3C and D), suggesting
that CD1d engagement is sufficient to induce cytokine production
by ILC3s. Consistent with these data, we detected increased IL-22
production by ILC3s after CD1d cross-link by ELISA and intracellu-
lar staining (Fig 3E–G). ILC3s are known to produce IL-22 in
response to a variety of environmental cues including cytokines (i.e.
IL-23) or Toll-like receptor (TLR) ligands; and combinations of such
stimuli may skew ILC3 activation and differentiation [4,38]. Interest-
ingly, we observed that CD1d engagement on ILC3s acts synergisti-
cally with IL-23 to induce increased IL-22 production (Fig 3D–G). It
seems likely that in the context of an immune response CD1d
signals could function together with other factors (i.e. IL-23, IL-1b,
TLR ligands) to modulate ILC3 activation and subsequently control
the local cytokine milieu to maintain homeostasis and/or regulate
inflammatory or infectious responses. Although the molecular
mechanisms by which CD1d engagement modulates IL-22 produc-
tion will require further investigation, it has been recently shown
that CD1d engagement in IEC leads to STAT3 phosphorylation and
STAT3-dependent cytokine secretion [14]. Interestingly, activated
STAT3 can directly bind the IL22 locus on ILC3s controlling IL-22
production [39], which may suggest STAT proteins as a possible
mechanistic link between CD1d signalling and IL-22 secretion.
Finally, we tested whether ILC3s could participate in CD1d-
mediated immune responses in vivo. To explore this, we
administered aGalCer to WT mice, either intravenously or orally,
and analysed changes on the features of ILC3s in response to lipid
administration in the spleen or SI-LP, respectively (Fig 3H–J). We
detected activation of splenic ILC3, evidenced by CD69 up-regulation,
as early as 6 h after intravenous lipid injection (Fig 3H). More-
over, and in agreement with our in vitro data, ILC3s sorted from
◀ Figure 2. ILC3s internalize and present lipid antigens to iNKT cells.A Cells were cultured in the presence or absence of BODIPY-aGalCer at 4 or 37°C as indicated. Flow cytometry profiles and percentages of BODIPY-aGalCer+ DC or
ILC3 from the indicated tissues incubated at 4°C (white bars) or 37°C (grey bars) are shown (n = 3).
B WT mice were intravenously injected with BODIPY-aGalCer or PBS (control); lipid uptake was analysed by flow cytometry in the depicted populations from the
spleen 16 h after lipid injection (n = 3). Numbers indicate percentage of cells in the depicted gates.
C IL-2 secretion by DN32.D3 cells co-cultured with ILC3 sort-purified from mLN or spleen as indicated, pulsed (+) or not () with aGalCer and with or without aCD1d-
blocking antibody.
D–F Sort-purified ILC3s were preincubated with aGalCer (ILC3(aGal)) or PBS (ILC3(cont)) and adoptively transferred into WT recipients. (D) Experimental protocol; (E) fold
change in mRNA expression for the indicated cytokines in iNKT cells sort-purified from spleen, mLN or SI-LP of mice injected with aGalCer-loaded ILC3s. Gene
expression was measured by qPCR, normalized to GAPDH and presented as expression relative to iNKT cells sort-purified from mice injected with control ILC3s
(n = 3–5). (F) Intracellular cytokine staining (left) and percentage of cytokine+ cells (right) in splenic iNKT cells from ILC3-recipient mice (n = 3). Numbers indicate
percentage of cells in the depicted gates. **P < 0.01, two-tailed unpaired t-test.
Data information: Graphs represent mean  SEM. Data are from more than two independent experiments.
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aGalCer-injected mice showed a marked increase in the expression
of IL22 in comparison with ILC3s from control mice (Fig 3I). Also,
oral administration of aGalCer resulted in increased IL22 production
by intestinal ILC3s (Fig 3J), in line with a functional role for ILC3s
in the regulation of lipid-mediated immunity within the intestine.
Although IL-22 generally supports epithelial barrier function and
tissue repair, it can also promote proinflammatory responses and its
levels are often high in chronic inflammatory conditions [40].
A C
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Figure 3. Engagement of CD1d on ILC3s induces IL-22 production.
A, B Flow cytometry plots showing gating strategy (A) and percentage of ILC populations (from LinCD45+CD127+ cells, B) in mLN from WT (n = 4) and CD1d-deficient
(n = 3) mice.
C Fold change in mRNA expression for the indicated cytokines in ILC3s after antibody-mediated CD1d cross-link (n = 3). Gene expression was measured by qPCR and
normalized to GAPDH and to the mRNA expression levels in control ILC3s. *P < 0.05 two-tailed unpaired t-test.
D Fold change in IL22 mRNA expression in ILC3s after antibody-mediated CD1d cross-link and/or IL-23 stimulation (n = 4). Gene expression was measured by qPCR
and normalized to GAPDH and to the mRNA expression levels in control ILC3s. **P < 0.01 two-tailed unpaired t-test.
E IL-22 detection by ELISA in the supernatant of ILC3s cultured in the presence of aCD1d and/or IL-23 (n = 3). *P < 0.05 two-tailed unpaired t-test.
F, G Intracellular cytokine staining (F) and percentage of IL-22+ ILC3s (G) after stimulation with aCD1d, IL-23 and/or IL-1b. *P < 0.05, **P < 0.01 two-tailed unpaired
t-test (n = 4–8)
H WT mice were i.v. injected with aGalCer or PBS (control) and activation of splenic ILC3s was assessed by flow cytometry as CD69 up-regulation at 6 or 16 h after
injection. Grey filled profile, ILC3 from aGalCer-injected mice; empty profile, ILC3 from PBS-injected mice; dotted line, CD45 cells. Right graph, percentage of CD69+
ILC3s 6 h after injection of aGalCer (grey) or PBS (white) (n = 3). *P < 0.05 two-tailed unpaired t-test.
I, J Fold change in mRNA expression for the indicated cytokines in ILC3s sort-purified from spleen (I) or SI-LP (J) 6 h after intravenous (I) or oral (J) aGalCer
administration. Gene expression was measured by qPCR and normalized to GAPDH and to the expression levels in ILC3s sort-purified from PBS-injected mice
(n = 3). *P < 0.05, **P < 0.01 two-tailed unpaired t-test.
Data information: Graphs represent mean  SEM.
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Moreover, IL-22 contributes to the control of bacterial and
fungal infection, and to protective barrier functions during viral
infections [41]. Since lipid-dependent activation of immune cells
modulates the outcome of a variety of infectious and inflammatory
diseases [10,11,14,16], it is likely that ILC3s contribute to lipid-
mediated immunity in those contexts through secretion of IL-22,
consequently shaping the initiation or development of the immune
response.
All together, our data identify a novel pathway for immune
regulation mediated by CD1d expression on ILC3s. We show that
ILC3s can internalize and present lipids on CD1d and that CD1d-
dependent activation of ILC3s induces secretion of IL-22. This
pathway could have implications for a variety of immune
responses where CD1d-dependent immunity plays a central role
[10,11]. For instance, CD1d contributes to the functional regulation
of immune cells in a variety of autoimmune disorders (such as
IBD or systemic lupus erythematosus) consequently shaping the
initiation and/or progression of the immune response [42–45].
Accordingly, CD1d expression is down-regulated on IECs from
patients with IBD and on B cells from patients with systemic lupus
erythematosus, which correlates with abnormal function of IECs, B
cells and NKT cells in these diseases. Thus, similarly to the protec-
tive role exerted by epithelial CD1d in intestinal inflammation by
controlling IL-10 secretion, CD1d on ILC3s may contribute to the
regulation of immunity by modulating the production of IL-22.
Analyses of ILCs in human tissues will be crucial to define the
expression of the different CD1 isoforms (CD1a-d) in the ILC fami-
lies and therefore identify their role in the regulation of iNKT cells
in homeostasis and disease. Further studies will allow defining the
mechanisms that control CD1d expression on ILC3s and the role of
the ILC-NKT cell axis in different diseases providing a novel target
for immune intervention.
Materials and Methods
Reagents and mice
C57BL/6 WT mice were purchased from Charles River and CD1d/
mice were bred at King’s College London. All experiments were
approved by the King’s College London’s Animal Welfare and Ethi-
cal Review Body and the United Kingdom Home Office (project
licence 70/7907). iNKT hybridoma DN32.D3 was from A. Bendelac
(University of Chicago). aGalCer was purchased from BioVision.
PBS57-loaded CD1d tetramers were provided by the NIH Tetramer
Core Facility. BODIPY-aGalCer was synthesized according to previ-
ously published protocols [46].
Tissue preparation and flow cytometry
Tissues were processed as previously described [3] and single-cell
suspensions were used for flow cytometry. For SI-LP lymphocyte
preparations, intestines were isolated, PP removed, and intestines
were flushed with cold PBS and cut open longitudinally. Tissues
were incubated 20 min at 37°C in HBSS, 1 mM EDTA, 5% FCS to
remove epithelial cells and intraepithelial lymphocytes. The lamina
propria layer was isolated after incubation for 40 min at 37°C with
collagenase (1.5 mg/ml) and DNase (100 lg/ml). Spleen and mLN
were harvested and single-cell suspensions obtained by mincing the
tissue through a 45-lm strainer.
Flow cytometry analyses were performed in FACS buffer contain-
ing PBS, 1% BSA and 1% FCS. Anti-mouse CD16/32 (clone 2.4G2,
Biolegend) was used to block non-specific antibody binding. After-
wards cells were stained with the following antibodies, all from
Biolegend unless specified otherwise: B220 (clone RA3-6B2), CCR6
(clone 29-2L17), CD117 (clone 2B8), CD11b (clone M1/70), CD11c
(clone N418), CD127 (clone A7R34), CD1d (clone 1B1), CD3 (clone
145-2C11), CD4 (clone GK1.5), CD45.2 (clone 104), CD5 (clone 53-
7.3), CD69 (clone H1.2F3), CD90 (clone 53-2.1), I-A/I-E (clone M5-
114.15.2), NKp46 (clone 29A1.4), TCR-b (clone H57-587), sca-1
(clone, D7), T-bet (clone 4B10), PLZF (clone 9E12), GATA-3 (clone
TWAJ, eBioscience), RORct (clone B2D, eBioscience).
For intracellular staining, cells were fixed and permeabilized
with Foxp3/Transcription Factor Staining Buffer Set (eBioscience).
Dead cells were excluded from the analyses using a fixable viability
stain (Biolegend). Flow cytometry data were collected on a FACS-
Canto II flow cytometer (BD Biosciences) and were analysed with
FlowJo software (Tree Star).
Isolation, culture and stimulation of ILC3s
For purification of ILC3s, single-cell suspensions from mLNs and
spleens were prepared by mincing the tissue through a 45-lm
strainer. Splenic ILC3s were enriched by using lineage cell
depletion kit (Miltenyi Biotec). ILC3s were further purified by cell
sorting as CD45+CD127+CD117+B220CD3CD5CD11cCD11b
cells [3,9,28] with a FACSAria II (BD Biosciences). Sorted ILC3s
were cultured in complete RPMI medium supplemented with 10%
FCS. For cross-linking experiments, ILCs were expanded for
5–8 days with IL-7 (50 ng/ml) and IL-2 (100 ng/ml) as described
[28,47].
Surface CD1d was cross-linked by incubation of ILC3s with anti-
CD1d antibody (clone 1B1) followed by goat anti-rat IgG as
described [14,21]. In some experiments, cells were incubated with
recombinant IL-23 (100 ng/ml, Biolegend) or IL-1b (100 ng/ml,
Biolegend) and/or anti-CD1d. For intracellular cytokine staining
after cross-linking, ILC3s were incubated with brefeldin A (5 lg/ml,
Biolegend) for the final 2 h of stimulation, fixed and permeabilized
with Fix/Perm buffer set (Biolegend) and stained for cytokine
production with anti-mouse IL-22 (1H8PWSR, eBioscience). Dead
cells were excluded from the analyses using a fixable viability stain
(Biolegend). IL-22 was measured in the cultures’ supernatant using
IL-22 ELISA MAX Deluxe (Biolegend).
For analysis of BODIPY-aGalCer acquisition, ILC3s were
incubated with fluorescent lipids (100 ng/ml) for 4–6 h before
flow cytometry analyses. For analysis of fluorescent lipid uptake
in vivo, mice were intravenously injected with BODIPY-aGalCer
(1 lg/mouse) in 200 ll of PBS. Lipid uptake was analysed by flow
cytometry in the spleen 16 h after injection.
For aGalCer presentation analysis, sorted cells were incubated
for 2 h with aGalCer (100 ng/ml), washed extensively and cultured
(5 × 103 cells/well) with 2 × 104 cells/well of DN32.D3 cells for
16 h. IL-2 concentration was determined by a standard sandwich
ELISA in the supernatant of the culture medium, using anti-IL-2
(JES6-1A12) antibody for capture and biotinylated anti-IL-2 (JES6-
5H4) antibody for detection (both from Biolegend).
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ILC3 adoptive transfer and iNKT cell activation
ILC3s were incubated for 2 h with aGalCer (100 ng/ml) or PBS,
washed extensively and adoptively transferred into WT recipients
(0.5–1 × 105 cells/mouse). Recipient mice were euthanized 18–24 h
following transfer and iNKT cell activation was measured by qPCR
and flow cytometry.
For qPCR analyses, iNKT cells were sort-purified from the spleen,
mLN and SI-LP of recipient mice as TCR-b+CD1d-tetramer+B220
cells and RNA was extracted as described below.
For intracellular IFN-c and IL-4 staining, single-cell suspension
were prepared and stained with B220, TCR-b and CD1d-tetramer
prior to fixation and permeabilization with Fix/Perm buffer set
(Biolegend). Fixed cells were stained with anti-mouse IFN-c
(XMG1.2, Biolegend) and anti-IL-4 (11B11, Biolegend). Dead cells
were excluded from the analyses using a fixable viability stain
(Biolegend).
Quantitative real-time PCR
RNA samples were prepared using RNeasy Mini Kit (Qiagen) and
cDNAs were synthesized with iScript Select cDNA Synthesis Kit
(Bio-Rad). For gene expression analyses, we used SYBR green
Master kit (Bio-Rad) and the following primers: GAPDH-F: 50-ACGA
CCCCTTCATTGAC-30; GAPDH-R: 50-TCCACGACATACTCAGCAC-30;
LTA-F: 50-GCCATTCCCACTCCCATCTACCTG-30; LTA-R: 50-CGCACC
CACGGTCCTTGAAGTC-30; LTB-F: 50-ACCTCATAGGCGCTTGGAT
G-30; LTB-R: 50-ACGCTTCTTCTTGGCTCGC-30; IL17A-F: 50-AGCAAG
AGATCCTGGTCCTGAA-30; IL17A-R: 50-CATCTTCTCGACCCTGAAA
GTGA-30; IL22-F: 50-GACCAAACTCAGCAATCAGCTC-30; IL22-R:
50-TACAGACGCAAGCATTTCTCAG-30; CD40L-F: 50-AGCTGGTGCTT
CTGTGTTTGTC-30; CD40L-R: 50-AAGATGAGAAGCCAACTCTGTG
G-30; TNFSF13-F: 50-ACCCAGAAGCACAAGAAGAAGC-30; TNFSF13-R:
50-GTACTGGTTGCCACATCACCTC-30; TNFSF13B-F: 50-AGCTGAGCC
TGGTGACCCTGTTC-30; TNFSF13B-R: 50-TCTCATCTCCTTCTTCCAG
CCTCGC-30; IL4-F: 50-AAGAACACCACAGAGAGTGAGCTC-30; IL4-R:
50-TTTCAGTGATGTGGACTTGGACTC-30; IL10-F: 50-AGAAGCATGG
CCCTGAAATCAAGG-30; IL-10-R: 50-CTTGTAGACACCTTGGTCTTG
GAG-30; IFNG-F: 50-GCCATCAGCAACAACATAAGCGTC-30; IFNG-R:
50-CCACTCGGATGAGCTCATTGAATG-30; CD1D-F: 50-GAATGACACCT
GCCCCCTATT-30; CD1D-R: 50-ACCCACACAGGTTTTGGGTA-30. Reac-
tions were run in a real-time PCR system (ABI7900HT; Applied
Biosystems).
Expanded View for this article is available online.
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